APRO vs Bio Protocol — how do they compare? APRO trades at Rp2,783 (market cap Rp701,62M, Rp288,95M 24h volume), while Bio Protocol trades at Rp438.98 (market cap Rp996,68M, Rp165,43M 24h volume). The key difference: Bio Protocol is the larger of the two by market cap, and APRO's circulating supply is 250M / 1B AT (25%) versus 2,3B / 3,3B BIO (69%) for Bio Protocol. Which is the better fit depends on your goals — on Pluang, investors hold APRO for 5 Days and Bio Protocol for 18 Days on average.
| AT | BIO | |
|---|---|---|
Market Cap | Rp701,62M | Rp996,68M |
Volume (24h) | Rp288,95M | Rp165,43M |
Circulating Supply | 250M / 1B AT (25%) | 2,3B / 3,3B BIO (69%) |
Typical Hold Time | 5 Days | 18 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bio Protocol (BIO) trades at Rp438.8 with a market cap of Rp996.68M, showing neutral technical signals overall. The token is currently testing the pivot point at Rp440, with immediate support at Rp430 and resistance at Rp454. With 69% of max supply in circulation and an average hold time of 18 days, the token exhibits moderate liquidity. Recent technical indicators show mixed signals with bearish moving averages but neutral oscillators.
Outlook remains neutral with key opportunities in potential breakout above Rp454 resistance. Major risks include low market cap vulnerability to volatility and limited fundamental developments. Investors should monitor trading volume patterns and broader crypto market sentiment for directional cues.
What Pluang investors did over the last 30 days
Allora is an open intelligence platform that enables AI systems to learn, adapt, and improve together. It provides a shared layer where multiple models are combined, compared, and refined in real time, allowing users and developers to contribute to and benefit from collective intelligence.
Read more on AT →BIO Protocol enables global communities of scientists, patients, and investors to collectively fund, develop, and co-own new drugs and therapeutics through its network of Biotech Decentralized Autonomous Organizations (BioDAOs). The protocol's innovative approach addresses critical gaps in traditional scientific funding, particularly in areas such as rare diseases, longevity research, and emerging health challenges.
Read more on BIO →